Epigenomics Moves Methylation-Based Prostate Cancer Prognostic to Affy Platform

Dec 13, 2006

NEW YORK (GenomeWeb News) — Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.

The company said a concordance study showed a 98-percent agreement between the two platforms.

Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Featured White Papers

MLPA Assays on the SeqStudio Genetic Analyzer

Optimized NGS Library Preparation with Acoustic Liquid Handling

May

01

Featured Webinar

Analytical Validation of a Liquid Biopsy Assay for High-Sensitivity Molecular Profiling

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May

08

Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

Main menu